简讯

发布时间：

2026年9月23日 下午12:31（太平洋时间）
图片版权：
VISWA COLLURU / ENVEDA
Marina Temkin
Enveda融资3.11亿美元，将更多源自自然的AI药物推进至临床试验阶段

Enveda是一家利用人工智能在自然界中发现新药的生技初创公司，已以20亿美元的估值完成了3.11亿美元的E轮融资。这轮由Catalio Capital Management领投、Iconiq等机构参投的新资金，使Enveda的估值较12个月前实现翻倍。

Enveda的理念是，强大的药物可以从植物和微生物中获取，而非在实验室中从头合成。Viswa Colluru是Recursion Pharmaceuticals的早期员工，他于2019年创立了Enveda，旨在利用AI及其他技术加速这些新药的发现过程。

尽管AI尚未产生任何获得FDA批准的药物，但Enveda正属于将AI发现的候选药物推进至人体临床试验的一波公司之列。该初创公司目前正在对患者测试多种药物，包括一种针对严重皮肤状况的药物，以及另一种旨在帮助在停用GLP-1类药物后维持减重效果的药物。

主题

人工智能
生技与健康
临床试验
Enveda
简讯
初创企业
10月13日 – 15日
旧金山

您下一次重要的连接将在Disrupt发生。

与10,000多位创始人、风险投资人、运营人员和科技领袖建立联系。探索明天的突破，聆听塑造今日科技的力量，并在9月25日晚上11:59（太平洋时间）前预订以节省高达200美元的费用。

立即预订
通讯订阅
查看更多

订阅行业规模最大的科技新闻

TechCrunch每日新闻

每个工作日和周日，您都可以获得TechCrunch报道的精华内容。

将TechCrunch每日新闻添加到您的订阅选项中
TechCrunch移动出行

TechCrunch移动出行是您获取交通新闻和见解的目的地。

将TechCrunch移动出行添加到您的订阅选项中
初创企业周刊

初创企业是TechCrunch的核心，因此请每周接收我们最优质的报道。

将Startups Weekly添加到您的订阅选项中
StrictlyVC

为行业关键人物提供开启一天所需的资讯。

将StrictlyVC添加到您的订阅选项中
未选择任何通讯订阅。
订阅

提交您的电子邮件即表示您同意我们的条款和隐私声明。

相关
TECHCRUNCH DISRUPT 2026
TechCrunch Disrupt 2026期间的StrictlyVC：深入探讨风险投资不断变化的规则
TechCrunch活动
8小时前
初创企业
随着对AI训练数据需求的激增，Snorkel AI估值翻三倍至35亿美元
Marina Temkin
1天前
人工智能
Nscale的IPO将再次考验华尔街对集中押注AI的兴趣
Marina Temkin
1天前
生技与健康最新报道
简讯
Enveda融资3.11亿美元，将更多源自自然的AI药物推进至临床试验阶段
Marina Temkin
3小时前
TECHCRUNCH DISRUPT 2026
TechCrunch Disrupt 2026仅剩3天时间，可节省高达200美元并建立有影响力的联系
TechCrunch活动
8小时前
TECHCRUNCH DISRUPT 2026
展位桌位新增：在TechCrunch Disrupt 2026上展示您初创企业的最后机会
TechCrunch活动
1天前

IN BRIEF

Posted:

12:31 PM PDT · September 23, 2026
IMAGE CREDITS:
VISWA COLLURU / ENVEDA
Marina Temkin
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago.

The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques.

While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials. The startup is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.

Topics

AI
Biotech & Health
clinical trials
Enveda
In Brief
Startups
October 13 – 15
San Francisco

Your next big connection is at Disrupt.

Connect with 10,000+ founders, VCs, operators, and tech leaders. Explore tomorrow’s breakthroughs, hear what’s shaping tech today, and save up to $200 by Sept. 25 at 11:59 p.m. PT.

BOOK NOW
Newsletters
See More

Subscribe for the industry’s biggest tech news

TechCrunch Daily News

Every weekday and Sunday, you can get the best of TechCrunch’s coverage.

Add TechCrunch Daily News to your subscription choices
TechCrunch Mobility

TechCrunch Mobility is your destination for transportation news and insight.

Add TechCrunch Mobility to your subscription choices
Startups Weekly

Startups are the core of TechCrunch, so get our best coverage delivered weekly.

Add Startups Weekly to your subscription choices
StrictlyVC

Provides movers and shakers with the info they need to start their day.

Add StrictlyVC to your subscription choices
No newsletters selected.
Subscribe

By submitting your email, you agree to our Terms and Privacy Notice.

Related
TECHCRUNCH DISRUPT 2026
StrictlyVC at TechCrunch Disrupt 2026: Inside the changing rules of venture capital
TechCrunch Events
8 hours ago
STARTUPS
Snorkel AI triples valuation to $3.5B as demand for AI training data booms
Marina Temkin
1 day ago
AI
Nscale’s IPO will test Wall Street’s appetite for concentrated AI bets once again
Marina Temkin
1 day ago
Latest in Biotech & Health
IN BRIEF
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Marina Temkin
3 hours ago
TECHCRUNCH DISRUPT 2026
3 days left to save up to $200 and make impactful connections at TechCrunch Disrupt 2026
TechCrunch Events
8 hours ago
TECHCRUNCH DISRUPT 2026
Exhibit tables added: One last chance to showcase your startup at TechCrunch Disrupt 2026
TechCrunch Events
1 day ago